Skip to main content
. 2020 Sep 18;479(2):298–308. doi: 10.1097/CORR.0000000000001491

Fig. 4.

Fig. 4

A-B Patients with IPN at diagnosis have worse overall and metastasis-free survival compared with patients with normal staging chest CTs. (A) This figure shows overall survival for patients with no metastases, IPN, or metastases at diagnosis. At 2 years, patients with IPNs had an overall survival of 65% (95% CI 52 to 75) while those with no metastases at diagnosis had an overall survival rate of 83% (95% CI 78 to 87; p < 0.001). The worst outcomes were experienced by patients with metastases, whose 2-year overall survival was 45% (95% CI 32 to 57; p < 0.001). (B) This figure shows metastasis-free survival for patients with no metastases or IPNs at diagnosis. At 2 years, patients with IPNs had a metastasis-free survival of 35% (95% CI 24 to 46) while those with normal staging chest CTs had a metastasis-free survival of 77% (95% CI 71 to 81; p < 0.001).